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Edited by Laszlo NagyAbstract Knowledge of the regulatory factors associated with
down-regulation of adiponectin gene expression and up-regula-
tion of PAI-1 gene expression is crucial to understand the path-
ophysiological basis of obesity and metabolic diseases, and could
establish new treatment strategies for these conditions. We
showed that expression of 5-HT2A receptors was up-regulated
in hypertrophic 3T3-L1 adipocytes, which exhibited decreased
expression of adiponectin and increased expression of PAI-1.
5-HT2A receptor antagonists and suppression of 5-HT2A recep-
tor gene expression enhanced adiponectin expression. Activation
of Gq negatively regulated adiponectin expression, and inhibition
of mitogen-activated protein kinase reversed the Gq-induced ef-
fect. Moreover, the 5-HT2A receptor blockade reduced PAI-1
expression. These ﬁndings indicate that antagonism of 5-HT2A
receptors in adipocytes could improve the obesity-linked de-
creases in adiponectin expression and increases in PAI-1 expres-
sion.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The number of overweight individuals worldwide has
reached 2.1 billion, leading to an explosion of obesity-related
health problems associated with a high mortality rate. Obesity
is considered central to the metabolic syndrome and is associ-
ated with increases in the risk of an array of diseases, including
insulin resistance, type 2 diabetes, fatty liver disease, athero-
sclerosis, cardiovascular disease, degenerative disorders, and
some cancers [1–4].
Adipose tissue participates in the regulation of energy
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doi:10.1016/j.febslet.2008.07.044tant endocrine organ that secretes adipokines [5,6]. Adiponec-
tin is an antidiabetic and antiatherogenic adipokine [7–11]. In
obesity, hypertrophic adipocytes decrease their expression and
secretion of adiponectin and increase insulin-resistance causing
hormones, and lead to insulin resistance and diabetes [12–14].
Plasminogen activator inhibitor (PAI)-1 plays important
roles in the pathogenesis of cardiovascular events, promoting
both thrombosis and ﬁbrosis [15]. Human adipose tissue con-
tributes to the elevation of plasma PAI-1 concentrations ob-
served in obese subjects [16]. Knowledge of the regulatory
factors associated with down-regulation of adiponectin gene
expression and up-regulation of PAI-1 gene expression is cru-
cial for understanding the pathophysiological basis of obesity
and metabolic diseases and could establish new treatment
strategies for these conditions.
Sarpogrelate is a selective antagonist of 5-HT2A receptors,
widely used for patients with arteriosclerosis obliterans
(ASO) because of its vasodilating and antiplatelet eﬀects [17].
Sarpogrelate has recently been reported to increase plasma
concentrations of adiponectin in diabetic patients with ASO
by 2.6-fold at 3 months [18]. Sarpogrelate also increased circu-
lating adiponectin by 2.5-fold in patients with type 2 diabetes
who had elevated soluble E-selectin concentrations, platelet
activation, and endothelial injury markers [19]. Sarpogrelate
increases adiponectin concentrations in non-diabetic and
non-medicated diabetic patients with peripheral artery disease
[20]. The 5-HT2A receptor has been described as involved in 5-
HT-induced platelet activation and contraction of vascular
smooth muscle [21]. Neither the distribution of 5-HT receptor
subtypes in white adipose tissue nor the function of the 5-HT
signaling cascade in adipocytes has been determined.
It has been reported that sarpogrelate decreases serotonin-
induced PAI-1 mRNA expression in vascular endothelial cells
[22].
To verify the hypothesis that the expressions of adiponectin
and PAI-1 are modulated by 5-HT receptor stimuli, we exam-
ined the expression of 5-HT receptor subtypes in the 3T3-L1
preadipocyte, 3T3-L1 small adipocytes (Day 10 after induction
of adipocyte diﬀerentiation) and hypertrophic 3T3-L1 adipo-
cytes (Day 17 after induction). Expression of 5-HT2A receptor
mRNA was increased in hypertrophic adipocytes and in mes-
enteric adipose tissue of diabetic-obese mice, db/db mice,
which exhibit decreased expression of adiponectin andblished by Elsevier B.V. All rights reserved.
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involvement of the 5-HT2A receptor signaling cascade via
mitogen-activated protein kinase (MAPK)-dependent path-
ways in the regulation of adiponectin and PAI-1 expression.2. Materials and methods
2.1. Chemicals
Sarpogrelate was synthesized at Mitsubishi Tanabe Corporation.
Ketanserin, isobutylmethylxanthine, and dexamethasone, GW9662
were purchased from Sigma. Spiperone and PNU22394 were from TO-
CRIS. Pasteurella Multocida Toxin (rPMT), Ro31-8220, Go6850,
Go6983 and PD98059 were from Merck Calbiochem.
2.2. Cell culture, triglyceride content of adipocytes and glucose uptake
3T3-L1 cells (ATCC) were cultured on gelatin-coated plates in Dul-
becco Modiﬁed Eagles Medium containing 10% fetal bovine serum
(basal medium). Induction of diﬀerentiation into adipocyte phenotypes
was performed by treating conﬂuent cells with 0.5 mM isobutyl-meth-
ylxanthine, 0.25 lM dexamethasone, and 5 lg/ml insulin in basal med-
ium for 2 days, followed by treatment with 5 lg/ml insulin in basal
medium for 2 days. The cells were then maintained in basal medium.
Culture of cells on gelatin-coated plates allowed for long-term culture
of adipocytes. Culture of 3T3-L1 adipocytes for 35 days after induc-Fig. 1. Changes in lipid accumulation (A and D), gene expression of adipo
during diﬀerentiation of 3T3-L1 adipocytes. Comparisons of results at Day 1
the SAS system. *P < 0.05; **P < 0.01; ***P < 0.001 versus Day 10. Values ation of diﬀerentiation was possible. Cellular lipid accumulation on
Day 10 and Day 17 was determined by oil red 0 staining. Magniﬁca-
tion of microscope is 400·. Triglycerides were extracted with hexane/
2-propanol (3:2, v/v). Triglyceride content resolved in 2-propanol
was determined using determiner LTGII (KYOWA MEDEX Co.
Ltd, Tokyo). Cells were solubilized with 0.05 N NaOH to determine
protein concentrations using the Bradford method. Glucose uptake
was determined as follows. Cells were washed three times with PBS,
and were serum-deprived with serum-free DMEM for 2–4 h. After
the incubation with PBS containing 0.1% BSA with or without
100 nM insulin for 20 min, 0.5 lCi of [3H]2-deoxy-glucose was added,
then incubated for 10 min. Transport reaction was terminated with
two washes of ice-cold 0.3 mM phloretin. Insulin responses were
shown in % to basal glucose uptake.
2.3. Suppression of gene expression and RNA analysis
5-HT2A modulators were incubated in basal medium for 24 h on
Day 10 or Day 17. siRNA constructs were designed by DHARMA-
CON. Co. siRNA of pGL2, negative control for siRNA, or siRNA
of 5-HT2A receptor were transfected into 3T3-L1 adipocytes for 24 h
using Express-si Delivery (Genospectra Inc.). Sarpogrelate was added
to the basal medium for an additional 24 h. GW9662 were pre-incu-
bated in basal medium for 24 h before co-incubation of GW9662
and 5-HT2A antagonists for additional 24 h. Total RNA was extracted
using the 6100 system (Applied BioSystems Co.). Quantitative analysis
of adiponectin and PAI-1 by real-time PCR with cDNA was on an
ABI 7500 system. The primer sets and probes for adiponectin werenectin (B) and PAI-1 (C), and insulin-dependent glucose uptake (D)
0 and Day 14 or Day 17 were performed by Dunnett multiple test using
re means ± S.E. (n = 6 for B, C; n = 4–8 for D and E).
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ATGACGTTACTACAA-3 0, reverse primer, 5 0-CCATCCAACCTG-
CACAAGTTC-3 0 and the probe 5 0-CCTGCTTTGGTCCCTCCACC-
CAAG-30. For 36B4: forward primer 5 0-CCCTGAAGTG-
CTCGACATCA-3 0, reverse primer, 5 0-TGCGGACACCCTCCA-
GAA-3 0 and the probe 5 0-AGAGCAGGCCCTGCACTCTCGC-3 0.
The primers and probes for 5-HT receptor subtypes and PAI-1 were
from Applied Biosystems. The relative abundance of transcripts was
normalized to constitutive expression of 36B4.
2.4. Animals
All experiments in animal study were performed on 9–13 week-old
male db/db mice and wild-type C57BL/6 mice (Charles River Labora-
tories, Japan, Inc.). The animal care and procedures of the experiments
were approved by the Animal Care Committee of Mitsubishi Tanabe
Pharma Corporation.3. Results
3.1. Changes in expression levels of adiponectin and PAI-I and
lipid accumulation and insulin-dependent glucose uptake in
adipocytes during adipocyte diﬀerentiation and hypertrophy
To clarify whether the expression of adiponectin and PAI-1
is modulated by 5-HT receptor stimuli in adipocytes, we ﬁrst
examined the expression of adiponectin and PAI-1 genes dur-
ing diﬀerentiation and hypertrophy of 3T3-L1 adipocytes. Cel-
lular lipid accumulation was greater on Day 17 (hypertrophic
adipocytes) than on Day 10 (small adipocytes), and on Day 17
(Fig. 1A and D). Expression of adiponectin continued to in-
crease until Day 10, and was reduced on Day 17 compared
with on Day 10 (Fig. 1B). Expression of PAI-1 continued to
increase during diﬀerentiation and was signiﬁcantly elevated
on Day 17 compared with on Day 10 (Fig. 1C). Insulin-depen-
dent glucose uptake was most active on Day 10 and was de-Fig. 2. Changes gene expression of 5-HT2A receptor (A), 5-HT1A receptor (B
of 3T3-L1 adipocytes. Maximum values are presented as 100%. *P < 0.05; **
means ± S.E. (n = 6).creased on Day 17 compared with on Day 10 (Fig. 1E). The
triglyceride content of the cells continued to rise after the
induction of diﬀerentiation (Fig. 1D), appeared to correlate in-
versely with expression of the adiponectin gene and insulin-
dependent glucose uptake between Days 10 and 17, and was
proportional to expression of the PAI-1 gene and triglyceride
accumulation between Days 10 and 17. To determine whether
the 5-HT signaling cascade is involved in the regulation of
adiponectin and PAI-1, adipocytes on Day 10 were used as
adiponectin-abundant cells. Adipocytes on Day 17 were used
as hypertrophic cells to examine the eﬀects of 5-HT receptor
antagonism on down-regulated adiponectin.
3.2. Expression of 5-HT receptor subtypes in 3T3-L1
preadipocytes, adipocytes and mesenteric adipose tissue of
obese-diabetic mice
To address the possibility that the 5-HT signaling cascade
regulates adiponectin and PAI-1 mRNA, we studied the
expression of 5-HT receptors in 3T3-L1 preadipocytes before
induction of diﬀerentiation (Day 0) and during diﬀerentiation.
Expression of 5-HT2A receptors increased during diﬀerentia-
tion and remained high. It was signiﬁcantly elevated in Day
17 hypertrophic adipocytes compared with in Day 10
(Fig. 2A). Expression of 5-HT1A,1B,and 1D receptors was abun-
dant in preadipocytes but decreased after induction of diﬀeren-
tiation (Fig. 2B–D). Expression of 5-HT1A,1B,and 1D receptors
did not diﬀer between Day 10 and Day 17 (Fig. 2B and C).
Expression of all other 5-HT2B,2C, 4,5A,5B and7 receptors we
examined was undetectable at Day 0, Day 10, and Day 17.
Among the active 5-HT receptors (1A, 1B, 1D, and 2A), the
5-HT2A receptor was more abundant in hypertrophic adipo-
cytes that exhibited lower adiponectin expression.), 5-HT1B receptor (C), and 5-HT1D receptor (D) during diﬀerentiation
P < 0.01 versus Day 10. n.s., not signiﬁcant versus Day 10. Values are
Fig. 3. Expression levels of 5H-T2A receptor (A), adiponectin (B), PAI-1 (C), 5-HT1A receptor, 5-HT1B receptor, and 5-HT1D receptor (D) in
mesenteric adipose tissue in C57BL/6 mice (lean) and db/db mice. Values of lean mice are presented as 100%. *P < 0.05; **P < 0.01 versus lean. n.s.,
not signiﬁcant versus lean. Values are means ± S.E. (n = 5–8).
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examined the expression levels of 5-HT receptor subtypes,
adiponectin and PAI-1 in mesenteric adipose tissue of db/db
mice and wild-type C57BL/6 mice. The 5-HT2A receptor
mRNA levels in the mesenteric adipose tissues of db/db mice
were increased as compared with in lean control mice
(Fig. 3A). In the mesenteric adipose tissues of db/db mice,
adiponectin expression levels were reduced (Fig. 3B), and
PAI-1 expression levels were increased (Fig. 3C) as compared
with in lean control mice. Expression of the 5-HT1A and the 5-
HT1B recptors appeared to have tendency to be decreased in
db/db mice, but they did not diﬀer signiﬁcantly (P = 0.25,
0.34, respectively) (Fig. 3D). Expression levels of the 5-HTID
receptor did not diﬀer between db/db mice and lean mice
(Fig. 3D).
These ﬁndings, together with the observation that the 5-HT
was indeed present at the concentration of 0.64 lM equivalent
to human 5-HT in cell-culture serum, prompted us to attempt
to examine the 5-HT2A receptor in relation to its involvement
in adiponectin expression and PAI-1 expression.3.3. 5-HT2A receptor signals modulate adiponectin expression in
3T3-L1 adipocytes
PNU22394, a 5-HT2A/2B partial agonist, reduced adiponec-
tin gene expression (Fig. 4A), whereas sarpogrelate (Fig. 4B),
spiperone (Fig. 4C), and ketanserin (Fig. 4D), 5-HT2A receptor
antagonists, increased expression on Day 10. The eﬀects of sar-
pogrelate on adiponectin mRNA were inhibited by suppres-
sion of 5-HT2A receptor gene expression with siRNA
(Fig. 4E). Expression of adiponectin mRNA was increased
by siRNA-5-HT2A (Fig. 4E). Expression of the 5-HT2A recep-
tor was decreased by 70% by siRNA (data not shown). Sar-
pogrelate (Fig. 5A), spiperone (Fig. 5B), ketanserin
(Fig. 5C), which are 5-HT2A antagonists, increased adiponec-
tin expression on Day 17.
3.4. Downstream of activation of the 5-HT2A receptor in
regulation of adiponectin expression
Adiponectin mRNA was reduced to 10% of control level by
rPMT, a Gq activator (Fig. 6A). U-73122, a PLC inhibitor,
Ro31-8220, Go6850, Go6983, which are PKC inhibitors, had
Fig. 4. 5-HT2A receptor signals modulate adiponectin expression. PNU22394, a 5-HT2A receptor agonist (A), sarpogrelate, spiperone, or ketanserin,
5-HT2A receptor antagonists, (B–D) or rosiglitazone (Ros; PPARc agonist at 1 lM), was incubated on Day 10. (D) Sarpogrerate at 10 lMwas added
with siRNA of pGL2 or 5-HT2A receptor. Control value is presented as 100%. *P < 0.05; **P < 0.01 versus control. Values are means ± S.E. (n = 6).
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tin mRNA (data not shown). PD98059, a MAPK inhibitor,
partially reversed the eﬀects of rPMT (Fig. 6A). PNU22394,
a 5-HT2A agonist, had no eﬀect on adiponectin mRNA in
hypertrophic 3T3-L1 adipocytes on Day 17 (Fig. 6B), at which
point, adiponectin mRNA was down-regulated (Fig. 1B).
Ro31-8220, Go6983, PKC inhibitors, did not increase adipo-
nectin mRNA (data not shown). PD98059 signiﬁcantly amelio-
rated down-regulation of adiponectin mRNA on Day 17
(Fig. 6B).
We examined adiponectin mRNA using the PPAR (peroxi-
some proliferator-activated receptor) gamma antagonist
GW9662 to determine whether 5-HT2A antagonists can induce
adiponectin in the absence of signiﬁcant PPAR gamma activity
in Day 17 adipocytes. Co-incubation of PPARgamma signiﬁ-
cantly reduced the eﬀects of sarpogrelate, spiperone, andketanserin, which are 5-HT2A antagonists, on adiponectin
mRNA, at least partially, raising the possibility that the mech-
anism of 5-HT2A antagonists-induced adiponectin mRNA
might be dependent on activity of PPARgamma, at least in
part (Fig. 7A–C).
3.5. PAI-1 mRNA was decreased by sarpogrelate through 5-
HT2A receptor via MAPK
Sarpogrelate and siRNA of the 5-HT2A receptor each re-
duced PAI-1 mRNA expression in 3T3-L1 adipocytes
(Fig. 8A). The reduction by sarpogrelate was not shown in adi-
pocytes transfected with siRNA of 5-HT2A receptor (Fig. 8A).
PAI-1 mRNA was increased with rPMT, whereas PD98059 re-
versed the rPMT-induced augmentation (Fig. 8B). U-73122
and Ro31-8220 had no eﬀect on the increase of PAI-1 mRNA
in response to rPMT (data not shown).
Fig. 5. Sarpogrelate (A), spiperone (B), and ketanserin (C), 5-HT2A antagonists, increase adiponectin mRNA in 3T3-L1 adipocytes on Day 17.
Control value is presented as 100%. *P < 0.05 versus control. Values are means ± S.E. (n = 6).
Fig. 6. Adiponectin mRNA is modulated via MAPK. (A) rPMT
(10 ng/ml) with or without PD98059, a MAPK inhibitor, were
incubated on Day 10 (A) or Day17 (B). Control value is presented
as 100%. *P < 0.05; **P < 0.01 versus control. Values are means ± S.E.
(n = 6).
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The adipocyte diﬀerentiation program is coordinated by sev-
eral positive negative adipogenic molecules, including a variety
of growth factors, cytokines and hormones [23].We have reported that adiponectin has insulin-sensitizing ac-
tions and that obesity decreases adiponectin sensitivity, there-
by leading to insulin resistance, which in turn aggravates
hyperinsulinemia [24]. In this study, we focused on modulation
of adiponectin and PAI-1 gene expression to explore the role
of the 5-HT signaling cascade in obesity-linked changes in
expression of these two proteins. Expression of PAI-1 was in-
creased in hypertrophic 3T3-L1 adipocytes, which produced a
decrease in adiponectin expression. These results are consistent
with the adipocyte dysfunction shown in obesity and type 2
diabetes.
It is reported that sarpogrelate inhibits serotonin and colla-
gen-induced phosphatidic acid formation in rat platelets (IC50
value is 2.8 lM, Ki value is 100 nM for rat 5-HT2 receptor)
[17], and spiperone and ketanserin inhibit serotonin-induced
inositol phosphate production in rat uterine smooth muscle
cells at 1 lM (Ki values of spiperone and ketanserin for 5-
HT2A receptor are 3.5 nM and 2 nM, respectively) [25,26]. To-
gether with our results, it is possible that blockade of the 5-
HT2A receptor could result in an increase in adiponectin
expression. It is also possible that 5-HT2A antagonists have
other targets in adipocytes.
The augmentation of adiponectin expression by sarpogrelate
was inhibited by suppression of the 5-HT2A receptor gene
using siRNA and suppression of this gene also increased
adiponectin expression. In agreement with these ﬁndings, 5-
HT2A stimulation by rPMT, which activates Gq protein cou-
pled to the 5-HT2A receptor, decreased adiponectin expression.
These ﬁndings indicate that the 5-HT2A receptor signaling cas-
cade negatively regulates adiponectin expression. Moreover,
expression of the 5-HT2A receptor was up-regulated in the adi-
pose tissue of db/db mice and 3T3-L1 hypertrophic adipocytes,
in which adiponectin expression was down-regulated and PAI-
1 expression was up-regulated. These ﬁndings raised the
possibility that the increase in 5-HT2A receptor expression in
Fig. 7. 5-HT2A antagonists-induced the increase of adiponectin
expression depends on PPARgamma. Sarpogrelate at 10 lM (A),
spiperone at 1 lM (B), or ketanserin at 1 lM (C) with or without
GW9662 (10 lM) were incubated on Day17. *P < 0.05 versus control.
n.s., not signiﬁcant versus control. Values are mean ± S.E. (n = 6).
Fig. 8. 5-HT2A receptor signal cascade modulates PAI-1 mRNA. (A)
Sarpogrelate was incubated with or without siRNA of 5-HT2A
receptor. (B) rPMT (10 ng/ml) with or without PD98059 (10 lM)
were incubated with 3T3-L1 adipocytes on Day 10. Control value is
presented as 100%. *P < 0.05; **P < 0.01 versus control. Values are
means ± S.E. (n = 6).
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obesity-linked reduction in adiponectin expression.
Adiponectin receptor agonists and adiponectin sensitizers
should serve as versatile treatment strategies for obesity-linked
diseases such as diabetes and metabolic syndrome [27]. Long-
lasting 5-HT2A receptor blockade might increase adiponectin
expression down-regulated in obesity.
Transcriptional activity of PPARgamma which increases
adiponectin levels has been reported to decrease by MAPK
phosphorylation [28]. It has been reported that the 5-HT2A
receptor stimulates MAPK in pulmonary artery ﬁbroblasts
which causes proliferative signals [29]. 5-HT2A receptor stimu-
lation may decrease the expression of adiponectin by reduction
in the transcriptional activity of PPARgamma through activa-
tion of MAPK in adipocytes. These important issues should be
addressed in future studies.
The MAPK pathway activation has been reported to in-
crease in PAI-1 gene expression in kidney [30]. The 5-HT2A
receptor signaling cascade could modulate PAI-1 expression
through MAPK pathway activation in adipocytes.
It has been reported that arrestin binding to GPCR enables
MAPK activation [31]. Therefore, arrestin binding to the 5-HT2A receptor might be involved in the regulation of adipo-
nectin and PAI-1 through MAPK.
In conclusion, the results of this study reveal that 5-HT2A
receptor antagonism increases expression of adiponectin and
decreases PAI-1 expression via the 5-HT2A receptor signaling
cascade. Furthermore, obesity-linked up-regulation of 5-
HT2A receptor expression could cause down-regulation of
adiponectin expression. Antagonism of 5-HT2A receptors has
the potential to protect against risk factors for and contribute
to the treatment of cardiovascular diseases associated with
metabolic syndrome as a result of obesity-related, aberrant
adipocytokine metabolism.
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